Vir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The S
Vir Biotechnology Announces SOLSTICE Data to Be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL Congress 2024, taking place in Milan, Italy, June 5-8.
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Vir Biotechnology (VIR) and Alvotech (ALVO)
TD Cowen Sticks to Their Buy Rating for Vir Biotechnology (VIR)
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
Across the recent three months, 6 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish.The table below provides a co
Express News | HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Analysts Just Shipped A Dazzling Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
Vir Biotechnology, Inc. (NASDAQ:VIR) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased
Earnings Call Summary | Vir Biotechnology(VIR.US) Q1 2024 Earnings Conference
The following is a summary of the Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript:Financial Performance:VIR Biotechnology reported a Q1 2024 total revenue of $56.4 million, a decline fr
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Is Maintained at Neutral by JP Morgan
JP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $12
JP Morgan analyst Eric Joseph maintains Vir Biotechnology (NASDAQ:VIR) with a Neutral and raises the price target from $10 to $12.
Express News | Needham Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target
Vir Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 45.28% Needham → $15 Reiterates Buy → Buy 03/15/2024 965.38% HC Wainwright & Co. → $110 Reitera
Vir Biotechnology Currently Up Six Consecutive Days, On Track for Longest Winning Streak Since October 2022 -- Data Talk
Vir Biotechnology, Inc. ( VIR ) is currently at $10.19, up $1.01 or 11% --Would be highest close since April 1, 2024, when it closed at $10.20 --On pace for largest percent increase since Feb. 23, 2
Hold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial Uncertainty
Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)
Buy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment Milestones
Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Express News | Vir Biotechnology Inc : JP Morgan Raises Target Price to $12 From $10
Express News | Vir Biotechnology Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results